-$1.91 EPS Expected for La Jolla Pharmaceutical (LJPC) This Quarter

Wall Street analysts expect that La Jolla Pharmaceutical (NASDAQ:LJPC) will announce earnings of ($1.91) per share for the current fiscal quarter, according to Zacks Investment Research. Four analysts have issued estimates for La Jolla Pharmaceutical’s earnings. The highest EPS estimate is ($1.80) and the lowest is ($1.97). La Jolla Pharmaceutical reported earnings of ($1.21) per share during the same quarter last year, which would indicate a negative year-over-year growth rate of 57.9%. The company is scheduled to issue its next earnings results on Thursday, July 26th.

On average, analysts expect that La Jolla Pharmaceutical will report full year earnings of ($6.82) per share for the current fiscal year, with EPS estimates ranging from ($8.05) to ($4.50). For the next financial year, analysts expect that the firm will report earnings of ($3.91) per share, with EPS estimates ranging from ($5.79) to ($1.51). Zacks Investment Research’s earnings per share averages are an average based on a survey of research analysts that that provide coverage for La Jolla Pharmaceutical.

La Jolla Pharmaceutical (NASDAQ:LJPC) last announced its quarterly earnings data on Thursday, May 10th. The biopharmaceutical company reported ($2.22) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.48) by ($0.74). The business had revenue of $0.81 million during the quarter.



Several analysts have weighed in on LJPC shares. ValuEngine upgraded La Jolla Pharmaceutical from a “hold” rating to a “buy” rating in a research report on Wednesday, May 2nd. Zacks Investment Research upgraded La Jolla Pharmaceutical from a “sell” rating to a “hold” rating in a research report on Tuesday, April 17th. HC Wainwright lowered their price objective on La Jolla Pharmaceutical to $83.00 and set a “buy” rating for the company in a research report on Thursday, March 22nd. BidaskClub downgraded La Jolla Pharmaceutical from a “hold” rating to a “sell” rating in a research report on Wednesday, February 28th. Finally, Chardan Capital reiterated a “buy” rating and issued a $115.00 price objective on shares of La Jolla Pharmaceutical in a research report on Monday. Three equities research analysts have rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and an average price target of $58.00.

Several institutional investors and hedge funds have recently bought and sold shares of the company. WINTON GROUP Ltd purchased a new position in shares of La Jolla Pharmaceutical during the first quarter valued at approximately $276,000. Tang Capital Management LLC increased its stake in shares of La Jolla Pharmaceutical by 20.3% during the first quarter. Tang Capital Management LLC now owns 4,138,893 shares of the biopharmaceutical company’s stock valued at $123,256,000 after buying an additional 698,474 shares during the period. Cowen Inc. purchased a new position in shares of La Jolla Pharmaceutical during the first quarter valued at approximately $1,193,000. Highland Capital Management LP purchased a new position in shares of La Jolla Pharmaceutical during the first quarter valued at approximately $759,000. Finally, Scopia Capital Management LP purchased a new position in shares of La Jolla Pharmaceutical during the first quarter valued at approximately $17,217,000.

LJPC stock traded up $0.62 during midday trading on Tuesday, hitting $31.22. The company had a trading volume of 275,313 shares, compared to its average volume of 478,639. La Jolla Pharmaceutical has a 52 week low of $22.68 and a 52 week high of $41.36. The company has a market capitalization of $796.14 million, a P/E ratio of -5.77 and a beta of 1.40.

La Jolla Pharmaceutical Company Profile

La Jolla Pharmaceutical Company, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for life-threatening diseases. It offers GIAPREZA, an injection for intravenous infusion indicated to increase blood pressure in adults with septic or other distributive shock.

Get a free copy of the Zacks research report on La Jolla Pharmaceutical (LJPC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for La Jolla Pharmaceutical (NASDAQ:LJPC)

Receive News & Ratings for La Jolla Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for La Jolla Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply